Login to Your Account



Two studies give new insights into Alzheimer’s biomarkers

By Anette Breindl
Science Editor

Friday, March 7, 2014
Clinical trials for Alzheimer’s disease find themselves with a frustrating conundrum these days. The scientific evidence for what is the root problem of the disease keeps getting better – and clinical trials based on that scientific evidence keeps going nowhere. At last count, more than a dozen phase III trials in a row have failed to meet their endpoints. Most recently, those include Gammagard (Baxter International Inc.), bapineuzumab (Pfizer Inc., Johnson & Johnson and Elan Corp. plc, now part of Perrigo Co. plc) and solanezumab (Eli Lilly and Co). Biopharma companies keep trying, though, spurred by both the importance of the problem and the giant market that awaits anyone who can actually develop a disease-modifying drug.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription